Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Drug Found to Limit Allergic Reaction to Peanuts

By HospiMedica staff writers
Posted on 27 Mar 2003
A study has shown that an experimental drug can help people with peanut allergies avoid life-threatening reactions. More...
The study was published in the March 14, 2003, issue of The New England Journal of Medicine and was also presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in Denver (CO, USA).

Food allergy symptoms can range from nausea and itching to anaphylactic shock and death. Researchers found that an anti-IgE antibody raised the average level at which study participants began reacting to peanuts, from about half a peanut to almost nine peanuts. They estimate that most of the 50-100 US annual fatal reactions to peanuts occur after an allergic person accidentally eats the equivalent of just one or two peanuts. Existing medications, including epinephrine, are taken only after the peanuts have been eaten and are not always effective.

The IgE molecule binds to a group of cells called mast cells, which then trigger the allergic response. The experimental drug, TNX-901, is a genetically engineered antibody that binds to the IgE molecule and prevents it from triggering allergic response. Stopping the response before it begins is considered a major advance. In the study, nearly a quarter of the patients receiving the highest dose of the drug consumed the equivalent of about 24 peanuts with no reaction. While many of them still reacted to peanuts after the injections, they could eat more peanuts without a reaction and reacted less vigorously to the peanuts they did eat.

TNX-901 was developed by Tanox (Houton, TX, USA). The study was conducted by researchers from the National Jewish Medical and Research Center (Denver, CO, USA) and the Mount Sinai School of Medicine (New York, NY, USA).

"Anti-IgE therapy is not a cure for peanut allergy,” said Hugh Sampson, M.D., of Mount Sinai School of Medicine. "But because the amount patients could consume without serious reaction would be greatly increased, the fear of accidental ingestion that detracts from quality of life for many patients would be eliminated.”





Related Links:
Tanox
National Jewish Medical and Research Center
Mount Sinai School of Medicine

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.